The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Adalimumab (Humira) and Biosimilar Market Research Report 2025

Global Adalimumab (Humira) and Biosimilar Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1739055

No of Pages : 97

Ask Your Query

Synopsis
Adalimumab is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation.

Global Adalimumab (Humira) and Biosimilar market is projected to reach US$ 15520 million in 2029, increasing from US$ 22420 million in 2022, with the CAGR of -5.1% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Adalimumab (Humira) and Biosimilar market research.

The expiration of patents for adalimumab (Humira) has emerged as a significant driver in the biosimilar market. Adalimumab is a widely used biologic medication for autoimmune diseases. The patent expiry allows for the entry of biosimilar versions of Humira, which are highly similar and offer a more cost-effective alternative. This increased competition fosters price reduction and improved accessibility for patients, addressing the growing demand for affordable treatments. Furthermore, regulatory support for biosimilars has further bolstered their adoption, ensuring safety, efficacy, and quality. Overall, the patent expiration and regulatory support are key drivers propelling the adalimumab biosimilar market forward.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Adalimumab (Humira) and Biosimilar market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company

  • AbbVie
  • Eisai
  • Cadila Healthcare
  • Torrent Pharmaceuticals
  • Amgen
  • Boehringer Ingelheim
  • Novartis
  • Samsung Bioepis
  • Viatris
  • Pfizer
  • Fresenius Kabi
  • Coherus

Segment by Type

  • Syringe
  • Pen

Segment by Application

  • Ankylosing Spondylitis
  • Rheumatoid Arthritis
  • Crohn’s Disease
  • Other

Consumption by Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE)

The Adalimumab (Humira) and Biosimilar report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source

Index

1 Adalimumab (Humira) and Biosimilar Market Overview
1.1 Product Overview and Scope of Adalimumab (Humira) and Biosimilar
1.2 Adalimumab (Humira) and Biosimilar Segment by Type
1.2.1 Global Adalimumab (Humira) and Biosimilar Market Value Comparison by Type (2023-2029)
1.2.2 Syringe
1.2.3 Pen
1.3 Adalimumab (Humira) and Biosimilar Segment by Application
1.3.1 Global Adalimumab (Humira) and Biosimilar Market Value by Application: (2023-2029)
1.3.2 Ankylosing Spondylitis
1.3.3 Rheumatoid Arthritis
1.3.4 Crohn’s Disease
1.3.5 Other
1.4 Global Adalimumab (Humira) and Biosimilar Market Size Estimates and Forecasts
1.4.1 Global Adalimumab (Humira) and Biosimilar Revenue 2018-2029
1.4.2 Global Adalimumab (Humira) and Biosimilar Sales 2018-2029
1.4.3 Global Adalimumab (Humira) and Biosimilar Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Adalimumab (Humira) and Biosimilar Market Competition by Manufacturers
2.1 Global Adalimumab (Humira) and Biosimilar Sales Market Share by Manufacturers (2018-2023)
2.2 Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Adalimumab (Humira) and Biosimilar Average Price by Manufacturers (2018-2023)
2.4 Global Adalimumab (Humira) and Biosimilar Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Adalimumab (Humira) and Biosimilar, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Adalimumab (Humira) and Biosimilar, Product Type & Application
2.7 Adalimumab (Humira) and Biosimilar Market Competitive Situation and Trends
2.7.1 Adalimumab (Humira) and Biosimilar Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Adalimumab (Humira) and Biosimilar Players Market Share by Revenue
2.7.3 Global Adalimumab (Humira) and Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Adalimumab (Humira) and Biosimilar Retrospective Market Scenario by Region
3.1 Global Adalimumab (Humira) and Biosimilar Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Adalimumab (Humira) and Biosimilar Global Adalimumab (Humira) and Biosimilar Sales by Region: 2018-2029
3.2.1 Global Adalimumab (Humira) and Biosimilar Sales by Region: 2018-2023
3.2.2 Global Adalimumab (Humira) and Biosimilar Sales by Region: 2024-2029
3.3 Global Adalimumab (Humira) and Biosimilar Global Adalimumab (Humira) and Biosimilar Revenue by Region: 2018-2029
3.3.1 Global Adalimumab (Humira) and Biosimilar Revenue by Region: 2018-2023
3.3.2 Global Adalimumab (Humira) and Biosimilar Revenue by Region: 2024-2029
3.4 North America Adalimumab (Humira) and Biosimilar Market Facts & Figures by Country
3.4.1 North America Adalimumab (Humira) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Adalimumab (Humira) and Biosimilar Sales by Country (2018-2029)
3.4.3 North America Adalimumab (Humira) and Biosimilar Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Adalimumab (Humira) and Biosimilar Market Facts & Figures by Country
3.5.1 Europe Adalimumab (Humira) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Adalimumab (Humira) and Biosimilar Sales by Country (2018-2029)
3.5.3 Europe Adalimumab (Humira) and Biosimilar Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Adalimumab (Humira) and Biosimilar Market Facts & Figures by Country
3.6.1 Asia Pacific Adalimumab (Humira) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Adalimumab (Humira) and Biosimilar Sales by Country (2018-2029)
3.6.3 Asia Pacific Adalimumab (Humira) and Biosimilar Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Adalimumab (Humira) and Biosimilar Market Facts & Figures by Country
3.7.1 Latin America Adalimumab (Humira) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Adalimumab (Humira) and Biosimilar Sales by Country (2018-2029)
3.7.3 Latin America Adalimumab (Humira) and Biosimilar Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Adalimumab (Humira) and Biosimilar Market Facts & Figures by Country
3.8.1 Middle East and Africa Adalimumab (Humira) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Adalimumab (Humira) and Biosimilar Sales by Country (2018-2029)
3.8.3 Middle East and Africa Adalimumab (Humira) and Biosimilar Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Adalimumab (Humira) and Biosimilar Sales by Type (2018-2029)
4.1.1 Global Adalimumab (Humira) and Biosimilar Sales by Type (2018-2023)
4.1.2 Global Adalimumab (Humira) and Biosimilar Sales by Type (2024-2029)
4.1.3 Global Adalimumab (Humira) and Biosimilar Sales Market Share by Type (2018-2029)
4.2 Global Adalimumab (Humira) and Biosimilar Revenue by Type (2018-2029)
4.2.1 Global Adalimumab (Humira) and Biosimilar Revenue by Type (2018-2023)
4.2.2 Global Adalimumab (Humira) and Biosimilar Revenue by Type (2024-2029)
4.2.3 Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Type (2018-2029)
4.3 Global Adalimumab (Humira) and Biosimilar Price by Type (2018-2029)
5 Segment by Application
5.1 Global Adalimumab (Humira) and Biosimilar Sales by Application (2018-2029)
5.1.1 Global Adalimumab (Humira) and Biosimilar Sales by Application (2018-2023)
5.1.2 Global Adalimumab (Humira) and Biosimilar Sales by Application (2024-2029)
5.1.3 Global Adalimumab (Humira) and Biosimilar Sales Market Share by Application (2018-2029)
5.2 Global Adalimumab (Humira) and Biosimilar Revenue by Application (2018-2029)
5.2.1 Global Adalimumab (Humira) and Biosimilar Revenue by Application (2018-2023)
5.2.2 Global Adalimumab (Humira) and Biosimilar Revenue by Application (2024-2029)
5.2.3 Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Application (2018-2029)
5.3 Global Adalimumab (Humira) and Biosimilar Price by Application (2018-2029)
6 Key Companies Profiled
6.1 AbbVie
6.1.1 AbbVie Corporation Information
6.1.2 AbbVie Description and Business Overview
6.1.3 AbbVie Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.1.4 AbbVie Adalimumab (Humira) and Biosimilar Product Portfolio
6.1.5 AbbVie Recent Developments/Updates
6.2 Eisai
6.2.1 Eisai Corporation Information
6.2.2 Eisai Description and Business Overview
6.2.3 Eisai Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Eisai Adalimumab (Humira) and Biosimilar Product Portfolio
6.2.5 Eisai Recent Developments/Updates
6.3 Cadila Healthcare
6.3.1 Cadila Healthcare Corporation Information
6.3.2 Cadila Healthcare Description and Business Overview
6.3.3 Cadila Healthcare Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Cadila Healthcare Adalimumab (Humira) and Biosimilar Product Portfolio
6.3.5 Cadila Healthcare Recent Developments/Updates
6.4 Torrent Pharmaceuticals
6.4.1 Torrent Pharmaceuticals Corporation Information
6.4.2 Torrent Pharmaceuticals Description and Business Overview
6.4.3 Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Product Portfolio
6.4.5 Torrent Pharmaceuticals Recent Developments/Updates
6.5 Amgen
6.5.1 Amgen Corporation Information
6.5.2 Amgen Description and Business Overview
6.5.3 Amgen Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Amgen Adalimumab (Humira) and Biosimilar Product Portfolio
6.5.5 Amgen Recent Developments/Updates
6.6 Boehringer Ingelheim
6.6.1 Boehringer Ingelheim Corporation Information
6.6.2 Boehringer Ingelheim Description and Business Overview
6.6.3 Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Product Portfolio
6.6.5 Boehringer Ingelheim Recent Developments/Updates
6.7 Novartis
6.6.1 Novartis Corporation Information
6.6.2 Novartis Description and Business Overview
6.6.3 Novartis Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Novartis Adalimumab (Humira) and Biosimilar Product Portfolio
6.7.5 Novartis Recent Developments/Updates
6.8 Samsung Bioepis
6.8.1 Samsung Bioepis Corporation Information
6.8.2 Samsung Bioepis Description and Business Overview
6.8.3 Samsung Bioepis Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Samsung Bioepis Adalimumab (Humira) and Biosimilar Product Portfolio
6.8.5 Samsung Bioepis Recent Developments/Updates
6.9 Viatris
6.9.1 Viatris Corporation Information
6.9.2 Viatris Description and Business Overview
6.9.3 Viatris Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Viatris Adalimumab (Humira) and Biosimilar Product Portfolio
6.9.5 Viatris Recent Developments/Updates
6.10 Pfizer
6.10.1 Pfizer Corporation Information
6.10.2 Pfizer Description and Business Overview
6.10.3 Pfizer Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Pfizer Adalimumab (Humira) and Biosimilar Product Portfolio
6.10.5 Pfizer Recent Developments/Updates
6.11 Fresenius Kabi
6.11.1 Fresenius Kabi Corporation Information
6.11.2 Fresenius Kabi Adalimumab (Humira) and Biosimilar Description and Business Overview
6.11.3 Fresenius Kabi Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Fresenius Kabi Adalimumab (Humira) and Biosimilar Product Portfolio
6.11.5 Fresenius Kabi Recent Developments/Updates
6.12 Coherus
6.12.1 Coherus Corporation Information
6.12.2 Coherus Adalimumab (Humira) and Biosimilar Description and Business Overview
6.12.3 Coherus Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Coherus Adalimumab (Humira) and Biosimilar Product Portfolio
6.12.5 Coherus Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Adalimumab (Humira) and Biosimilar Industry Chain Analysis
7.2 Adalimumab (Humira) and Biosimilar Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Adalimumab (Humira) and Biosimilar Production Mode & Process
7.4 Adalimumab (Humira) and Biosimilar Sales and Marketing
7.4.1 Adalimumab (Humira) and Biosimilar Sales Channels
7.4.2 Adalimumab (Humira) and Biosimilar Distributors
7.5 Adalimumab (Humira) and Biosimilar Customers
8 Adalimumab (Humira) and Biosimilar Market Dynamics
8.1 Adalimumab (Humira) and Biosimilar Industry Trends
8.2 Adalimumab (Humira) and Biosimilar Market Drivers
8.3 Adalimumab (Humira) and Biosimilar Market Challenges
8.4 Adalimumab (Humira) and Biosimilar Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock